- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.05. | Glucotrack reports Q1 results | 1 | Seeking Alpha | ||
| GLUCOTRACK Aktie jetzt für 0€ handeln | |||||
| 14.05. | GlucoTrack, Inc.: Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | 398 | GlobeNewswire (Europe) | Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring... ► Artikel lesen | |
| 14.05. | Glucotrack, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 14.05. | Glucotrack, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 07.05. | Glucotrack submits long-term implantable CBGM for FDA IDE | - | MassDevice | ||
| 07.05. | Glucotrack beantragt FDA-Zulassung für implantierbaren Blutzuckermonitor | 4 | Investing.com Deutsch | ||
| 07.05. | Glucotrack, Inc.: Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology | 84 | GlobeNewswire (Europe) | RUTHERFORD, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization... ► Artikel lesen | |
| 30.04. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.04. | Glucotrack, Inc.: Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology | 2 | GlobeNewswire (USA) | ||
| 21.04. | Glucotrack veröffentlicht Peer-Review-Studie zur Langzeitstabilität seines Glukosesensors | 3 | Investing.com Deutsch | ||
| 14.04. | Glucotrack wandelt Schuldschein über 600.000 US-Dollar in Aktien um | 4 | Investing.com Deutsch | ||
| 14.04. | Glucotrack, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.03. | GlucoTrack, Inc.: Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | 358 | GlobeNewswire (Europe) | Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued patents... ► Artikel lesen | |
| 30.03. | Glucotrack GAAP EPS of -$31.22 | 1 | Seeking Alpha | ||
| 30.03. | Glucotrack, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | GlucoTrack Shares Surge 34% On FDA Submission Progress For Implantable Glucose Monitor | 2 | RTTNews | ||
| 27.03. | GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech | 1 | Benzinga.com | ||
| 27.03. | Glucotrack to submit continuous blood glucose monitor for FDA IDE in early Q2 | 1 | MassDevice | ||
| 27.03. | Glucotrack, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Glucotrack plant FDA-Antrag für implantierbaren Blutzuckersensor | 1 | Investing.com Deutsch |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,170 | +0,60 % | Eckert&Ziegler mit Rekordsignal: Die Entwicklung die jetzt niemand auf dem Schirm hat - Verpassen Sie das nicht | ||
| SERNOVA BIOTHERAPEUTICS | 0,100 | +8,23 % | Sernova Biotherapeutics: Sernova Biotherapeutics Announces Closing of Recently Approved Financings | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 23, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) (XETRA: PSHO) ("Sernova" or the "Company"), a leading... ► Artikel lesen | |
| SYNLAB | 12,710 | 0,00 % | EQS-News: SYNLAB: Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden | EQS-News: SYNLAB
/ Schlagwort(e): Sonstiges
Die Region Stockholm beauftragt SYNLAB mit dem Ausbau ihrer medizinischen Diagnostikdienstleistungen in Schweden
31.03.2026... ► Artikel lesen | |
| NUGEN MEDICAL DEVICES | 0,016 | +13,89 % | NuGen Medical Devices Inc.: NuGen Files Patent for Ready-to-Fill COP/COC Needle-Free Injection Nozzle, Advancing Prefilled Nozzle Technology | Toronto, Ontario--(Newsfile Corp. - March 25, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"), a leader in needle-free drug delivery, today announced the filing of a new patent covering... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| UNIDOC HEALTH | 0,064 | -6,67 % | UniDoc Health Corp.: UniDoc Reflects on Successes One Year After AMD Telemedicine Software Purchase | AMD Telemedicine software and related systems now fully integrated; UniDoc Connect used at more than 800 sites across 48 countries VANCOUVER, BC / ACCESS Newswire / May 21, 2026 / UniDoc Health Corp.... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: 150.000 Aktien gekauft - das ist der Grund! | Die Aktie von Sonoma Pharmaceuticals ist Zockern aus der sharedeals.de-Community seit Jahren bekannt. Mehrfach wurden dreistellige Kurs-Peaks innerhalb kürzester Zeit für herausragend lukrative Trading-Exits... ► Artikel lesen | |
| CO-DIAGNOSTICS | 3,705 | 0,00 % | Co-Diagnostics Reports First Quarter 2026 Financial Results | Advancing Global Commercialization Through CoSara Regulatory Progress and Regional Expansion
Executing Clinical Strategy with Upper Respiratory Submission Preparation... ► Artikel lesen | |
| MEDIVOLVE | - | - | Medivolve Inc (2): OSC cites Bharti, Said for disclosure failures | ||
| QUIDELORTHO | 10,680 | +4,40 % | QuidelOrtho Corporation: QuidelOrtho Reports First Quarter 2026 Financial Results | ? LEX Diagnostics Acquisition Expected to Accelerate Growth in Point-of-Care Molecular Diagnostics ?? Key Product Launches in U.S. and International Markets Expected... ► Artikel lesen | |
| QUEST DIAGNOSTICS | 165,80 | +1,50 % | Quest Diagnostics declares $0.86 dividend | ||
| VERU | 2,210 | +4,74 % | Veru Inc.: Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | --Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027- --Company to host conference call and... ► Artikel lesen | |
| LIFEWARD | 6,280 | -3,24 % | Lifeward Ltd.: Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform | Veteran physician- medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience- mobility technologies, and metabolic disease... ► Artikel lesen | |
| SENSEONICS | 5,150 | +4,67 % | Senseonics Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TEMPEST THERAPEUTICS | 1,770 | -0,56 % | Tempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update | Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) Announced Cincinnati Children's Applied Gene and... ► Artikel lesen |
Das Unternehmen GLUCOTRACK INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -16,39 % bei einem Aktienkurs von 0,464 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLUCOTRACK INC finden Sie auf Wallstreet Online.